A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

被引：0
|
作者：
J E Ward
T Karrison
G Chatta
M Hussain
D Shevrin
R Z Szmulewitz
P H O'Donnell
W M Stadler
E M Posadas
机构：
[1] Section of Hematology/Oncology,Department of Medicine
[2] University of Chicago,Division of Hematology/Oncology, Department of Medicine
[3] University of Pittsburgh,Department of Internal Medicine
[4] University of Michigan,undefined
[5] Northshore University Health System,undefined
[6] Samuel Oschin Comprehensive Cancer Institute,undefined
[7] Cedars-Sinai Medical Center,undefined
来源：
Prostate Cancer and Prostatic Diseases | 2012年 / 15卷
关键词：
intermittent androgen suppression; tyrosine kinase inhibitors; pazopanib randomized consortium trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：87 / 92
页数：5
相关论文
共 50 条
  • [21] Ixabepilone, Mitoxantrone, and Prednisone for Metastatic Castration-Resistant Prostate Cancer After Docetaxel-Based Therapy A Phase 2 Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Harzstark, Andrea L.
    Rosenberg, Jonathan E.
    Weinberg, Vivian K.
    Sharib, Jeremy
    Ryan, Charles J.
    Smith, David C.
    Pagliaro, Lance C.
    Beer, Tomasz M.
    Liu, Glenn
    Small, Eric J.
    CANCER, 2011, 117 (11) : 2419 - 2425
  • [22] Phase I/II safety and pharmacokinetic (PK) study of ARN-509 in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase I results of a Prostate Cancer Clinical Trials Consortium study
    Rathkopf, Dana E.
    Danila, Daniel Costin
    Morris, Michael J.
    Slovin, Susan F.
    Steinbrecher, Jill Elise
    Arauz, Gabrielle
    Rix, Peter J.
    Maneval, Edna Chow
    Chen, Isan
    Fox, Josef J.
    Fleisher, Martin
    Larson, Steven M.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [23] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium
    Harzstark, A. L.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Mi, J.
    Small, E. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [24] Erratum to: Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium
    Deborah A. Bradley
    Stephanie Daignault
    Charles J. Ryan
    Robert S. DiPaola
    Kathleen A. Cooney
    David C. Smith
    Eric Small
    Paul Mathew
    Mitchell E. Gross
    Mark N. Stein
    Alice Chen
    Kenneth J. Pienta
    June Escara-Wilke
    Gerald Doyle
    Mahmoud Al-Hawary
    Evan T. Keller
    Maha Hussain
    Investigational New Drugs, 2011, 29 : 1517 - 1518
  • [25] Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
    Kindler, Hedy Lee
    Wroblewski, Kristen
    Wallace, James A.
    Hall, Michael J.
    Locker, Gershon
    Nattam, Sreenivasa
    Agamah, Edem
    Stadler, Walter M.
    Vokes, Everett E.
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (01) : 382 - 386
  • [26] Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium
    Hedy Lee Kindler
    Kristen Wroblewski
    James A. Wallace
    Michael J. Hall
    Gershon Locker
    Sreenivasa Nattam
    Edem Agamah
    Walter M. Stadler
    Everett E. Vokes
    Investigational New Drugs, 2012, 30 : 382 - 386
  • [27] Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium
    Rosenberg, Jonathan E.
    Ryan, Charles J.
    Weinberg, Vivian K.
    Smith, David C.
    Hussain, Maha
    Beer, Tomasz M.
    Ryan, Christopher W.
    Mathew, Paul
    Pagliaro, Lance C.
    Harzstark, Andrea L.
    Sharib, Jeremy
    Small, Eric J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (17) : 2772 - 2778
  • [28] Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.
    Small, E. J.
    Beer, T. M.
    Weinberg, V. K.
    Higano, C. S.
    Nordquist, L. T.
    Rosenberg, J. E.
    Alumkal, J. J.
    Yu, E. Y.
    Sun, J.
    Lin, A. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial
    Cheung, Eric
    Pinski, Jacek
    Dorff, Tanya
    Groshen, Susan
    Quinn, David I.
    Reynolds, C. Patrick
    Maurer, Barry J.
    Lara, Primo N., Jr.
    Tsao-Wei, Denice D.
    Twardowski, Przemyslaw
    Chatta, Gurkamal
    McNamara, Mark
    Gandara, David R.
    CLINICAL GENITOURINARY CANCER, 2009, 7 (01) : 43 - 50
  • [30] Phase II trial of intravenous carboplatin (C), oral everolimus (E), and prednisone (P) in docetaxel-pretreated (DP) metastatic castrate-resistant prostate cancer (mCRPC): A Prostate Cancer Clinical Trials Consortium study.
    Veeraputhiran, Muthu Kumaran
    Shevrin, Daniel H.
    Stein, Mark N.
    Heilbrun, Lance K.
    Smith, Daryn
    Li, Jing
    Dickow, Brenda
    Heath, Elisabeth I.
    Vaishampayan, Ulka N.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345